Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | PYGM | P11217 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401860 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL4557921 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL19326781 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9309804 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9699515 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL5551957 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL25366499 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL19326770 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL22409570 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9060748 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2022-11-03 | — | — | US | claimed |
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| EP-2352992-B1 | METHODS FOR IDENTIFICATION OF MICROORGANISMS USING SPECTROSCOPY | BIO MERIEUX INC (US) | 2020-04-22 | — | — | EP | claimed |
| EP-2364356-B1 | METHODS FOR DETECTION AND IDENTIFICATION OF MICROORGANISMS | BIO MERIEUX INC (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2710031-B9 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2710031-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2017-09-13 | — | — | EP | claimed |
| EP-2370452-B1 | PROCESS FOR EXTRACTING PROTEINS FROM FFPE BIOLOGICAL TISSUE SAMPLES | PORTO CONTE RICERCHE S R L (IT) | 2017-04-05 | — | — | EP | claimed |
| EP-0810876-B1 | INFLUENZA VIRUS SUBUNIT CONJUGATES | AVENTIS PASTEUR INC (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1566437-B1 | Adsorption of nucleic acids to a solid phase | ROCHE DIAGNOSTICS GMBH (DE) | 2007-06-13 | — | — | EP | claimed |
| EP-0564495-B2 | TISSUE FACTOR BASED PROTHROMBIN TIME REAGENT | CORVAS INT INC (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1069131-B1 | Methods for separating particulate substrates from solution while minimizing particle loss | QIAGEN GMBH (DE) | 2006-03-15 | — | — | EP | claimed |
| EP-1091652-B1 | CHEESE RIPENING PROCESS | DANISCO UK LTD (GB) | 2005-03-30 | — | — | EP | claimed |
| EP-0675898-B1 | USE OF MOLECULARLY IMPRINTED POLYMERS FOR STEREO- AND/OR REGIOSELECTIVE SYNTHESIS | MOSBACH KLAUS H (SE) | 2001-11-21 | — | — | EP | claimed |
| EP-0564495-B1 | TISSUE FACTOR BASED PROTHROMBIN TIME REAGENT | CORVAS INT INC (US) | 1999-05-06 | — | — | EP | claimed |
| EP-0445135-B1 | IMMOGENICALLY ACTIVE FRACTIONS OF BORRELIA BURGDORFERI | SYMBICOM AB (SE) | 1997-03-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | GAA 979/4885PYGB 1472/4885PYGL 1698/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | GAA 2546/4885PYGB 2276/4885PYGL 689/4885 |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.